TapewireFind a company

person · Reporting owner

FRANK MORGAN C.

Disclosed activity across 6 companies

Tapewire entity
32790
SEC CIK
0001593072

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BRAIN SCIENTIFIC INC.BRSF · Entity 12425610% ownerJune 15, 2022August 04, 2022
Modular Medical, Inc.MODD · Entity 7488Director · 10% ownerSeptember 30, 2026October 01, 2026
NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 780810% ownerJanuary 15, 2021January 21, 2021
SANUWAVE Health, Inc.SNVW · Entity 7321Director · Chief Executive OfficerSeptember 30, 2026October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivativeIndirectSee Footnote19,545,187 Reported balance Holding disclosure · report date 2022-06-15 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 19,545,187

F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common Stock, $0.001 par valueSEC Table I · non-derivativeIndirectSee Footnote12,816,831 Reported balance Holding disclosure · report date 2022-06-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 12,816,831

F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common Stock, $0.001 par valueSEC Table I · non-derivativeDirect8,028,706 Reported balance Holding disclosure · report date 2022-06-15 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 8,028,706

F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.

Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25IndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2022-06-15 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.

F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.

F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25IndirectSee FootnoteNot disclosed Reported balance Holding disclosure · report date 2022-06-15 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance Not disclosed

F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.

F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.

F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25DirectNot disclosed Reported balance Holding disclosure · report date 2022-06-15 · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · Balance Not disclosed

F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.

F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.

F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.

Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2031-10-01DirectNot disclosed Reported balance Holding disclosure · report date 2022-06-15 · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · Balance Not disclosed

F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference.

F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.

F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.

F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.

F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference.

Modular Medical, Inc.

Report date September 30, 2026 · Filed October 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2026-09-30Direct62 Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-09-30 · Grant · Acquired 62 · Balance 62

F1: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2026-09-30Direct312 Reported balance After 2026-09-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-30 · Grant · Acquired 250 · Balance 312

F1: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Filing footnotes · ownership attribution and instrument terms

F1: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

NEUROONE MEDICAL TECHNOLOGIES Corp

Report date January 15, 2021 · Filed January 21, 2021

Jointly reported with BESSER JAMES E, MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, Manchester Explorer, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect492,951 Reported balance Holding disclosure · report date 2021-01-15 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 492,951

Common StockSEC Table I · non-derivativeIndirectSee Footnotes4,750,000 Reported balance Holding disclosure · report date 2021-01-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 4,750,000

F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC.

F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2026-01-15DirectNot disclosed Reported balance Holding disclosure · report date 2021-01-15 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2026-01-15IndirectSee FootnotesNot disclosed Reported balance Holding disclosure · report date 2021-01-15 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC.

F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC.

F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SANUWAVE Health, Inc.

Report date September 30, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2031-09-30Direct11,286 Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-09-30 · Grant · Acquired 11,286 · Balance 11,286

F1: Options were fully vested at the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Options were fully vested at the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

FENNEC PHARMACEUTICALS INC.

Report date January 27, 2016 · Filed March 29, 2018

Jointly reported with MANCHESTER MANAGEMENT PR, LLC, MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P., BESSER JAMES E

Section 16 reporting ended · disclosed 2018-03-29. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote1,666,666 Last balance in matching sequence After 2018-03-28 transaction · row 24 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
15 source rows

Row 1 · 2018-03-08 · Sale · Disposed 10,000 · Balance 2,146,797

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 2 · 2018-03-12 · Sale · Disposed 18,560 · Balance 2,128,237

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 3 · 2018-03-13 · Sale · Disposed 16,934 · Balance 2,111,303

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 4 · 2018-03-14 · Sale · Disposed 13,600 · Balance 2,097,703

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 5 · 2018-03-16 · Sale · Disposed 6,423 · Balance 2,091,280

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 6 · 2018-03-16 · Sale · Disposed 2,120 · Balance 2,089,160

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 8 · 2018-03-19 · Sale · Disposed 200 · Balance 2,088,960

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 10 · 2018-03-20 · Sale · Disposed 4,200 · Balance 2,084,760

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 12 · 2018-03-20 · Sale · Disposed 15,183 · Balance 2,069,577

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 14 · 2018-03-21 · Sale · Disposed 210,311 · Balance 1,859,266

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 16 · 2018-03-22 · Sale · Disposed 20,000 · Balance 1,839,266

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 18 · 2018-03-23 · Sale · Disposed 3,500 · Balance 1,835,766

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 20 · 2018-03-27 · Sale · Disposed 22,707 · Balance 1,813,059

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 22 · 2018-03-28 · Sale · Disposed 605 · Balance 1,812,454

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Row 24 · 2018-03-28 · Sale · Disposed 145,788 · Balance 1,666,666

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common StockSEC Table I · non-derivativeDirect1,250,000 Last balance in matching sequence After 2018-03-28 transaction · row 25 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
10 source rows

Row 7 · 2018-03-16 · Sale · Disposed 2,120 · Balance 1,672,494

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 9 · 2018-03-19 · Sale · Disposed 200 · Balance 1,672,294

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 11 · 2018-03-20 · Sale · Disposed 4,200 · Balance 1,668,094

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 13 · 2018-03-20 · Sale · Disposed 15,183 · Balance 1,652,911

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 15 · 2018-03-21 · Sale · Disposed 210,311 · Balance 1,442,600

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 17 · 2018-03-22 · Sale · Disposed 20,000 · Balance 1,422,600

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 19 · 2018-03-23 · Sale · Disposed 3,500 · Balance 1,419,100

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 21 · 2018-03-27 · Sale · Disposed 22,707 · Balance 1,396,393

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 23 · 2018-03-28 · Sale · Disposed 605 · Balance 1,395,788

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Row 25 · 2018-03-28 · Sale · Disposed 145,788 · Balance 1,250,000

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Filing footnotes · ownership attribution and instrument terms

F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.

F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

FiEE, Inc.

Report date August 03, 2020 · Filed August 05, 2020

Jointly reported with MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P., BESSER JAMES E

Section 16 reporting ended · disclosed 2020-08-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.01 par valueSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-08-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-08-03 · Sale · Disposed 4,287,214 · Balance 0

F1: Manchester Management Company, LLC, a Delaware limited liability company ("Manchester"), is principally engaged in the business of providing investment management services. The reported securities are indirectly beneficially owned by Manchester as a result of it having investment discretion over certain advisory accounts it manages, including Manchester Explorer, L.P. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as a Managing Member of Manchester, and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester. Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common Stock, $0.01 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-08-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-08-03 · Sale · Disposed 2,857,643 · Balance 0

F2: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

Common Stock, $0.01 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-08-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2020-08-03 · Sale · Disposed 143,357 · Balance 0

F3: The reported securities are directly owned by James E. Besser in his personal capacity.

Common Stock, $0.01 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-08-03 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2020-08-03 · Sale · Disposed 142,857 · Balance 0

F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity.

Filing footnotes · ownership attribution and instrument terms

F1: Manchester Management Company, LLC, a Delaware limited liability company ("Manchester"), is principally engaged in the business of providing investment management services. The reported securities are indirectly beneficially owned by Manchester as a result of it having investment discretion over certain advisory accounts it manages, including Manchester Explorer, L.P. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as a Managing Member of Manchester, and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester. Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.

F3: The reported securities are directly owned by James E. Besser in his personal capacity.

F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 30, 2026 Filed Oct 3, 2026 01:06 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 11,286 $0.00 Strike: $4.71 $0.00
Disclosure

SEC source: 0001593072-26-000010 · form4-10022026_091006.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,286

Underlying: Common Stock · 11,286 shares

Expires 2031-09-30

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
September 30, 2026 Filed Oct 1, 2026 23:21 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 250 Not disclosed Strike: $1.95 Not disclosed
Disclosure

SEC source: 0000919574-26-006595 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312

Underlying: Common Stock · 250 shares

Expires 2026-09-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
September 30, 2026 Filed Oct 1, 2026 23:21 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 62 Not disclosed Strike: $1.95 Not disclosed
Disclosure

SEC source: 0000919574-26-006595 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62

Underlying: Common Stock · 62 shares

Expires 2026-09-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2026 Filed Jul 1, 2026 17:21 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 250 Not disclosed Strike: $4.88 Not disclosed
Disclosure

SEC source: 0000919574-26-004198 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312

Underlying: Common Stock · 250 shares

Expires 2036-06-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2026 Filed Jul 1, 2026 17:21 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 62 Not disclosed Strike: $4.88 Not disclosed
Disclosure

SEC source: 0000919574-26-004198 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62

Underlying: Common Stock · 62 shares

Expires 2036-06-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2026 Filed Jul 2, 2026 20:11 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 5,524 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001593072-26-000008 · form4-07022026_080711.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,524

Underlying: Common Stock · 5,524 shares

Expires 2031-06-30

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 21:09 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 3,208 $0.00 Strike: $17.29 $0.00
Disclosure

SEC source: 0001593072-26-000006 · form4-04022026_090409.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,208

Underlying: Common Stock · 3,208 shares

Expires 2031-03-31

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
March 31, 2026 Filed Apr 9, 2026 22:23 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 250 Not disclosed Strike: $4.55 Not disclosed
Disclosure

SEC source: 0000919574-26-002160 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312

Underlying: Common Stock · 250 shares

Expires 2036-03-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
March 31, 2026 Filed Apr 9, 2026 22:23 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 62 Not disclosed Strike: $4.55 Not disclosed
Disclosure

SEC source: 0000919574-26-002160 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62

Underlying: Common Stock · 62 shares

Expires 2036-03-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
January 30, 2026 Filed Feb 3, 2026 21:02 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 24,000 $0.00 Strike: $26.96 $0.00
Disclosure

SEC source: 0001593072-26-000004 · form4-02032026_090207.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2031-01-30

F1 · derivative.exercise_date: Options will vest in four equal installments on the last day of each quarter during 2026.

Read SEC document
December 31, 2025 Filed Jan 2, 2026 20:49 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 7,500 Not disclosed Strike: $0.36 Not disclosed
Disclosure

SEC source: 0000919574-26-000041 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 7,500 shares

Expires 2035-12-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 31, 2025 Filed Jan 2, 2026 20:49 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 1,875 Not disclosed Strike: $0.36 Not disclosed
Disclosure

SEC source: 0000919574-26-000041 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires 2035-12-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 31, 2025 Filed Jan 6, 2026 21:37 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 1,540 $0.00 Strike: $29.84 $0.00
Disclosure

SEC source: 0001593072-26-000002 · form4-01062026_090105.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,540

Underlying: Common Stock · 1,540 shares

Expires 2030-12-31

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 22:22 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 6,500 $21.04 $136,788.60
Disclosure

SEC source: 0000919574-25-007394 · ownership.xml · nonDerivative · entry 2

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 63,999

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.765 to $31.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 11, 2025 Filed Dec 15, 2025 22:22 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 13,500 $31.28 $422,277.30
Disclosure

SEC source: 0000919574-25-007394 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 70,499

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $31.05 to $31.525. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 10, 2025 Filed Dec 11, 2025 02:21 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 8,625 $30.39 $262,129.28
Disclosure

SEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 3

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 863,980

F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $30.01 to $30.90. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 10, 2025 Filed Dec 11, 2025 20:08 UTC Amendment SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 8,625 $30.39 $262,129.28
Disclosure

SEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 3

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 863,980

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.01 to $30.90. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 02:21 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 8,785 $30.58 $268,678.68
Disclosure

SEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 2

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 872,605

F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $30.00 to $31.71. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 20:08 UTC Amendment SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 8,785 $30.58 $268,678.68
Disclosure

SEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 2

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 872,605

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.00 to $31.71. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 08, 2025 Filed Dec 11, 2025 02:21 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 2,000 $31.60 $63,203.40
Disclosure

SEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 4

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $29.88 to $33.50. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
December 08, 2025 Filed Dec 11, 2025 02:21 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 125,400 $30.75 $3,856,050.00
Disclosure

SEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 881,390

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
December 08, 2025 Filed Dec 11, 2025 20:08 UTC Amendment SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 2,000 $31.60 $63,203.40
Disclosure

SEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 4

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $29.88 to $33.50. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
December 08, 2025 Filed Dec 11, 2025 20:08 UTC Amendment SANUWAVE Health, Inc. SNWV · Entity 7321 SaleCommon Stock, par value $0.001 125,400 $30.75 $3,856,050.00
Disclosure

SEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 881,390

F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
September 30, 2025 Filed Oct 2, 2025 21:49 UTC SANUWAVE Health, Inc. SNVW · Entity 7321 GrantStock Option (right to buy) · Derivative 1,342 $0.00 Strike: $37.48 $0.00
Disclosure

SEC source: 0001593072-25-000004 · form4-10022025_091010.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,342

Underlying: Common Stock · 1,342 shares

Expires 2030-09-30

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
September 30, 2025 Filed Oct 6, 2025 23:31 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 7,500 Not disclosed Strike: $0.70 Not disclosed
Disclosure

SEC source: 0000919574-25-005991 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 7,500 shares

Expires 2035-09-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
September 30, 2025 Filed Oct 6, 2025 23:31 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 1,875 Not disclosed Strike: $0.70 Not disclosed
Disclosure

SEC source: 0000919574-25-005991 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires 2035-09-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2025 Filed Jul 2, 2025 23:56 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 7,500 Not disclosed Strike: $0.68 Not disclosed
Disclosure

SEC source: 0000919574-25-003945 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 7,500 shares

Expires 2035-06-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2025 Filed Jul 2, 2025 23:56 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 1,875 Not disclosed Strike: $0.68 Not disclosed
Disclosure

SEC source: 0000919574-25-003945 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires 2035-06-30

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
June 30, 2025 Filed Jul 2, 2025 23:23 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 1,574 $0.00 Strike: $32.86 $0.00
Disclosure

SEC source: 0001437749-25-022045 · rdgdoc.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,574

Underlying: Common Stock · 1,574 shares

Expires 2030-06-30

F1 · derivative.exercise_date: Options were fully vested at the grant date.

Read SEC document
April 24, 2025 Filed Apr 28, 2025 16:39 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 125,000 $0.94 Strike: $0.94 $117,500.00
Disclosure

SEC source: 0000919574-25-002637 · ownership.xml · derivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

FRANK MORGAN C. · CIK 0001593072 · Director

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock, par value $0.001 per share · 125,000 shares

Expires 2035-04-24

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026.

F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
April 03, 2025 Filed Apr 7, 2025 20:11 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 1,761 $0.00 Strike: $29.80 $0.00
Disclosure

SEC source: 0001437749-25-011182 · rdgdoc.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,761

Underlying: Common Stock · 1,761 shares

Expires 2030-04-03

F1 · derivative.exercise_date: Options were fully vested on the grant date.

Read SEC document
March 31, 2025 Filed Apr 7, 2025 22:24 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 7,500 Not disclosed Strike: $1.10 Not disclosed
Disclosure

SEC source: 0000919574-25-002312 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 7,500 shares

Expires 2035-03-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
March 31, 2025 Filed Apr 7, 2025 22:24 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 1,875 Not disclosed Strike: $1.10 Not disclosed
Disclosure

SEC source: 0000919574-25-002312 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires 2035-03-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:34 UTC Modular Medical, Inc. MODD · Entity 7488 GrantCommon Stock Purchase Warrant · Derivative 78,125 $1.12 Strike: $1.12 $87,500.00
Disclosure

SEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 6

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

FRANK MORGAN C. · CIK 0001593072 · Director

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,125

Underlying: Common Stock, par value $0.001 per share · 78,125 shares

Expires 2029-03-25

F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F3 · derivative.exercise_date: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:34 UTC Modular Medical, Inc. MODD · Entity 7488 GrantCommon Stock Purchase Warrant · Derivative 260,416 $1.12 Strike: $1.12 $291,665.92
Disclosure

SEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 5

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

FRANK MORGAN C. · CIK 0001593072 · Director

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 260,416

Underlying: Common Stock, par value $0.001 per share · 260,416 shares

Expires 2029-03-25

F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F1 · derivative.exercise_date: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:34 UTC Modular Medical, Inc. MODD · Entity 7488 PurchaseCommon Stock, par value $0.001 per share 156,250 $1.92 $300,000.00
Disclosure

SEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 2

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

FRANK MORGAN C. · CIK 0001593072 · Director

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 422,000

F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:34 UTC Modular Medical, Inc. MODD · Entity 7488 PurchaseCommon Stock, par value $0.001 per share 520,832 $1.92 $999,997.44
Disclosure

SEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

FRANK MORGAN C. · CIK 0001593072 · Director

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,805,575

F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.

F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
January 31, 2025 Filed Feb 21, 2025 16:30 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $27.70 $0.00
Disclosure

SEC source: 0000919574-25-001610 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-01-31

F1 · shares: The options were granted to the Reporting Person in accordance with the Issuer's 2024 Equity Incentive Plan and are considered Non-Qualified Stock Options thereunder.

F2 · derivative.exercise_date: The options will vest, if at all, based on the completion of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on the applicable vesting date.

F3 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 31, 2024 Filed Jan 3, 2025 17:49 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 7,500 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0000919574-25-000052 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 7,500 shares

Expires 2034-12-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 31, 2024 Filed Jan 3, 2025 17:49 UTC Modular Medical, Inc. MODD · Entity 7488 GrantOption to purchase common stock · Derivative 1,875 Not disclosed Strike: $1.39 Not disclosed
Disclosure

SEC source: 0000919574-25-000052 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires 2034-12-31

F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.

F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 31, 2024 Filed Feb 19, 2025 19:04 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 1,559 $0.00 Strike: $22.76 $0.00
Disclosure

SEC source: 0000919574-25-001548 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,559

Underlying: Common Stock · 1,559 shares

Expires 2029-12-31

F1 · shares: The options were granted to the Reporting Person in accordance with the Issuer's 2024 Equity Incentive Plan and are considered Non-Qualified Stock Options thereunder.

F2 · derivative.exercise_date: The options will vest and become exercisable at the grant date.

F3 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
December 03, 2024 Filed Dec 4, 2024 18:05 UTC Modular Medical, Inc. MODD · Entity 7488 PurchaseCommon Stock, par value $0.001 per share 21,000 $1.68 $35,235.90
Disclosure

SEC source: 0000919574-24-007009 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,750

F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.65 to $1.73. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity.

Read SEC document
November 27, 2024 Filed Nov 29, 2024 10:00 UTC Modular Medical, Inc. MODD · Entity 7488 PurchaseCommon Stock, par value $0.001 per share 100,000 $1.69 $168,950.00
Disclosure

SEC source: 0000919574-24-006936 · ownership.xml · nonDerivative · entry 1

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner

Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization

JEB Partners, L.P. · CIK 0001093241 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,750

F1 · price: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2 · ownership.direct: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
October 22, 2024 Filed Feb 19, 2025 19:07 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 21,126 $0.00 Strike: $14.20 $0.00
Disclosure

SEC source: 0000919574-25-001549 · ownership.xml · derivative · entry 2

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 21,126 shares

Expires 2034-10-22

F2 · shares: The options were granted to the Reporting Person in accordance with the Issuer's 2024 Equity Incentive Plan and are considered Incentive Stock Options thereunder.

F3 · derivative.exercise_date: The options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.

F4 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
October 22, 2024 Filed Feb 19, 2025 19:07 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 GrantStock Option (right to buy) · Derivative 138,874 $0.00 Strike: $14.20 $0.00
Disclosure

SEC source: 0000919574-25-001549 · ownership.xml · derivative · entry 1

FRANK MORGAN C. · CIK 0001593072 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,874

Underlying: Common Stock · 138,874 shares

Expires 2034-10-22

F1 · shares: The options were granted to the Reporting Person in accordance with the Issuer's 2024 Equity Incentive Plan and are considered Non-Qualified Stock Options thereunder.

F3 · derivative.exercise_date: The options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.

F4 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."

Read SEC document
October 18, 2024 Filed Oct 23, 2024 17:03 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 OtherCommon Stock Purchase Warrant · Derivative 14,167 Not disclosed Strike: $25.13 Not disclosed
Disclosure

SEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 36

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 14,167 shares

Expires 2027-08-05

F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity.

Read SEC document
October 18, 2024 Filed Oct 23, 2024 17:03 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 OtherCommon Stock Purchase Warrant · Derivative 15,000 Not disclosed Strike: $15.00 Not disclosed
Disclosure

SEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 35

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 15,000 shares

Expires 2027-08-05

F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant.

F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant.

F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity.

Read SEC document
October 18, 2024 Filed Oct 23, 2024 17:03 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 OtherCommon Stock Purchase Warrant · Derivative 22,667 Not disclosed Strike: $25.13 Not disclosed
Disclosure

SEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 34

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 22,667 shares

Expires 2027-11-15

F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F8 · ownership.direct: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
October 18, 2024 Filed Oct 23, 2024 17:03 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 OtherCommon Stock Purchase Warrant · Derivative 24,000 Not disclosed Strike: $15.00 Not disclosed
Disclosure

SEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 33

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 24,000 shares

Expires 2027-11-15

F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant.

F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant.

F8 · ownership.direct: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
October 18, 2024 Filed Oct 23, 2024 17:03 UTC SANUWAVE Health, Inc. SNWV · Entity 7321 OtherCommon Stock Purchase Warrant · Derivative 6,375 Not disclosed Strike: $25.13 Not disclosed
Disclosure

SEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 32

MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization

Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization

MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization

BESSER JAMES E · CIK 0001512127 · Director by Deputization

FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 6,375 shares

Expires 2024-01-21

F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of

F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference.

F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis.

F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant.

F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.